New Zealand proposal to fund zoster vaccine

15 September 2017

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to fund the zoster vaccine (Zostavax) for the prevention of shingles (herpes zoster) from April 1, 2018, through a provisional agreement with Merck Sharpe & Dohme, the local subsidiary of US pharma giant Merck & Co (NYSE: MRK).

PHARMAC is proposing to list the zoster vaccine in Section B and in Part II of Section H of the Pharmaceutical Schedule for people aged 65 years and with a two-year catch up programme for people aged between 66 and 80 years inclusive.

Zostavax would be listed in Section I (National Immunisation Schedule) and Part II of Section H of the Pharmaceutical Schedule from April 1, 2018, at the following price (all NZ dollars) and subsidy (ex-manufacturer, excluding GST):

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK